Analysts expect that Agios Pharmaceuticals (NASDAQ:AGIO) will post ($1.60) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have provided estimates for Agios Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.65) and the highest is ($1.54). Agios Pharmaceuticals posted earnings of ($1.56) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 2.6%. The business is expected to report its next earnings report before the market opens on Friday, May 4th.
On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.25) per share for the current financial year, with EPS estimates ranging from ($6.51) to ($5.60). For the next financial year, analysts forecast that the business will post earnings of ($4.42) per share, with EPS estimates ranging from ($6.00) to ($0.01). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.65) by ($0.16). The business had revenue of $9.80 million for the quarter, compared to analyst estimates of $12.65 million. Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The company’s quarterly revenue was down 56.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.34) earnings per share.
In other news, major shareholder Corp /De/ Celgene purchased 851,154 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was purchased at an average cost of $67.00 per share, for a total transaction of $57,027,318.00. Following the completion of the transaction, the insider now owns 1,374,599 shares of the company’s stock, valued at $92,098,133. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Bowden sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.75, for a total value of $157,500.00. Following the sale, the insider now owns 2,881 shares of the company’s stock, valued at $226,878.75. The disclosure for this sale can be found here. Insiders have sold 159,880 shares of company stock valued at $12,661,668 over the last quarter. 5.43% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Xact Kapitalforvaltning AB purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $259,000. Alkeon Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 12.0% during the fourth quarter. Alkeon Capital Management LLC now owns 511,619 shares of the biopharmaceutical company’s stock worth $29,250,000 after purchasing an additional 54,858 shares in the last quarter. Teachers Advisors LLC increased its position in shares of Agios Pharmaceuticals by 13.5% during the fourth quarter. Teachers Advisors LLC now owns 53,591 shares of the biopharmaceutical company’s stock worth $3,064,000 after purchasing an additional 6,375 shares in the last quarter. HBK Investments L P purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $306,000. Finally, Two Sigma Investments LP increased its position in shares of Agios Pharmaceuticals by 18.8% during the fourth quarter. Two Sigma Investments LP now owns 53,265 shares of the biopharmaceutical company’s stock worth $3,045,000 after purchasing an additional 8,434 shares in the last quarter. Hedge funds and other institutional investors own 82.41% of the company’s stock.
Shares of AGIO stock traded up $0.99 during trading hours on Thursday, hitting $87.01. 255,053 shares of the company’s stock were exchanged, compared to its average volume of 590,903. The company has a market cap of $5,006.34, a price-to-earnings ratio of -12.91 and a beta of 1.98. Agios Pharmaceuticals has a fifty-two week low of $45.11 and a fifty-two week high of $89.33.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.